Palvella Therapeutics (PVLA) EBT (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly EBT of -$15.8 million for Q1 2026, down 92.63% year-over-year from -$214.0 million in Q1 2025, and down 23.39% quarter-over-quarter from -$12.8 million in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) EBT (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported EBT for 14 consecutive years, with -$15.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 92.63% year-over-year to -$15.8 million; the TTM figure through Mar 2026 stood at -$49.4 million (down 113.84% YoY), while the FY2025 annual figure was -$41.8 million, down 139.64% from the prior year.
- EBT declined to -$15.8 million in Q1 2026 per PVLA's latest filing, from -$12.8 million in the prior quarter.
- Across five years, EBT topped out at $15.0 million in Q4 2023 and bottomed at -$16.0 million in Q1 2023.
- Historically, EBT has averaged -$7.8 million across 5 years, with a median of -$9.5 million in 2025.
- Annual changes were most pronounced in 2023 — EBT soared 221.65% — and 2024, when it sank 366.92%.
- Palvella Therapeutics' EBT stood at -$12.3 million in 2022, then jumped by 221.65% to $15.0 million in 2023, then plunged by 126.36% to -$4.0 million in 2024, then tumbled by 223.41% to -$12.8 million in 2025, then fell by 23.39% to -$15.8 million in 2026.
- Business Quant data shows PVLA's EBT at -$15.8 million in Q1 2026, -$12.8 million in Q4 2025, and -$11.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | -21.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.87 Mn |
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | -12.78 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.95 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -4.17 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | 13.84 Mn |
| Sep 30, 2023 | -11.26 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | -15.15 Mn |
| Dec 31, 2022 | -11.17 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -12.20 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.01 Mn |
| Sep 30, 2021 | -19.01 Mn |